Back to today’s briefing

Story perspectives

Replimune Shares Soar 99% After FDA Resubmission Approval

10/20/2025

24 2 Full Breakdown

Summary

Story summary

Replimune Group Inc. shares surged 99.1% after the U.S. FDA accepted its resubmitted RP1 application with Bristol Myers Squibb's Opdivo.
The FDA decision is expected by April 10, 2026, following a July denial for insufficient data.
Replimune addressed the agency's concerns by providing additional information.
Analysts view this as positive for Replimune and the biotech sector despite caution.
Replimune Group Inc. is based in Woburn, Massachusetts.

History

Historical Context

The FDA Modernization Act of 1997, signed into law by President Bill Clinton, aimed to expedite drug approval processes, reducing review times from 30 months to 15 months. This act built on earlier reforms, including the 1962 Kefauver-Harris Amendment, which mandated proof of drug efficacy. The recent FDA Modernization Act 2.0, enacted in 2022, further eliminated mandatory animal testing, fostering innovation in drug development.

1 of 2

Story summary

Replimune Group Inc. shares surged 99.1% after the U.S. FDA accepted its resubmitted RP1 application with Bristol Myers Squibb's Opdivo.
The FDA decision is expected by April 10, 2026, following a July denial for insufficient data.
Replimune addressed the agency's concerns by providing additional information.
Analysts view this as positive for Replimune and the biotech sector despite caution.
Replimune Group Inc. is based in Woburn, Massachusetts.

1 / 2